Anti-TNF Therapies: a Comprehensive Analysis of Adverse Effects Associated with Immunosuppression

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2009 Dec 17

PMID 20013267

Citations 19

Authors

Victoria Connor

Affiliations

Soon will be listed here.

Abstract

Knowledge and understanding about the immunosuppressive properties of anti-TNF therapies and the adverse effects these causes have advanced over the last 10 years since the first of these drugs was approved. These drugs work by inhibiting tumour necrosis factor (TNF) in the body, which plays an essential role in the immune response to invading pathogens. Anti-TNF drugs have therapeutic value because high levels of TNF are thought to be part of the pathophysiology of many chronic inflammatory disorders such as rheumatoid arthritis and Crohn's disease. Anti-TNF drugs are usually well-tolerated, however, there have been reports of many potentially serious adverse effects. This article will comprehensively analyse these adverse effects; the incidence, symptoms and mechanisms will be discussed. In addition, the contraindications of this class of drugs will be explored and the detection and prevention methods that should be put in place by health care professionals who treat patients on these drugs will be described.

Citing Articles

Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review.

Mansilla-Polo M, Morgado-Carrasco D Dermatol Ther (Heidelb). 2024; 14(6):1389-1442.

PMID: 38763966 PMC: 11169156. DOI: 10.1007/s13555-024-01166-4.

Cholesterol-Modified Anti-Il6 siRNA Reduces the Severity of Acute Lung Injury in Mice.

Chernikov I, Bachkova I, Senkova A, Meschaninova M, Savin I, Vlassov V Cells. 2024; 13(9.

PMID: 38727303 PMC: 11083178. DOI: 10.3390/cells13090767.

Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.

Rommasi F, Nasiri M, Mirsaeidi M Mol Cell Biochem. 2022; 477(3):711-726.

PMID: 35013850 PMC: 8747854. DOI: 10.1007/s11010-021-04325-9.

Glycerol Improves Skin Lesion Development in the Imiquimod Mouse Model of Psoriasis: Experimental Confirmation of Anecdotal Reports from Patients with Psoriasis.

Choudhary V, Kaddour-Djebbar I, Custer V, Uaratanawong R, Chen X, Cohen E Int J Mol Sci. 2021; 22(16).

PMID: 34445455 PMC: 8395744. DOI: 10.3390/ijms22168749.

Antioxidant Therapy in Inflammatory Bowel Diseases.

Dziabowska-Grabias K, Sztanke M, Zajac P, Celejewski M, Kurek K, Szkutnicki S Antioxidants (Basel). 2021; 10(3).

PMID: 33803138 PMC: 8000291. DOI: 10.3390/antiox10030412.

References

Antoni C, Braun J . Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol. 2002; 20(6 Suppl 28):S152-7. View

Desai S, Furst D . Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006; 20(4):757-90. DOI: 10.1016/j.berh.2006.06.002. View

Callen J . Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg. 2007; 26(1):6-14. DOI: 10.1016/j.sder.2006.12.002. View

Moots R, Taggart A, Walker D . Biologic therapy in clinical practice: enthusiasm must be tempered by caution. Rheumatology (Oxford). 2003; 42(5):614-6. View

Lee S, Kavanaugh A . Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol. 2005; 116(4):900-5. DOI: 10.1016/j.jaci.2005.03.028. View

Wallis R . Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008; 8(10):601-11. DOI: 10.1016/S1473-3099(08)70227-5. View

Olsen N, Stein C . New drugs for rheumatoid arthritis. N Engl J Med. 2004; 350(21):2167-79. DOI: 10.1056/NEJMra032906. View

Wallis R, Ehlers S . Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum. 2005; 34(5 Suppl1):34-8. DOI: 10.1016/j.semarthrit.2005.01.009. View

Balakumar P, Singh M . Anti-tumour necrosis factor-alpha therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol. 2006; 99(6):391-7. DOI: 10.1111/j.1742-7843.2006.pto_508.x. View

10.

Furst D, Wallis R, Broder M, Beenhouwer D . Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006; 36(3):159-67. DOI: 10.1016/j.semarthrit.2006.02.001. View

11.

Kroesen S, Widmer A, Tyndall A, Hasler P . Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 2003; 42(5):617-21. DOI: 10.1093/rheumatology/keg263. View

12.

Atzeni F, Sarzi-Puttini P . Autoantibody production in patients treated with anti-TNF-alpha. Expert Rev Clin Immunol. 2010; 4(2):275-80. DOI: 10.1586/1744666X.4.2.275. View

13.

Danila M, Patkar N, Curtis J, Saag K, Teng G . Biologics and heart failure in rheumatoid arthritis: are we any wiser?. Curr Opin Rheumatol. 2008; 20(3):327-33. PMC: 4097098. DOI: 10.1097/BOR.0b013e3282fb03d8. View

14.

Robinson W, Genovese M, Moreland L . Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. Arthritis Rheum. 2001; 44(9):1977-83. DOI: 10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6. View